Article Sidebar

PDF
Date Published: 13/01/2022
Abstract Views: 426
Views PDF: 237
DOI: https://doi.org/10.51298/vmj.v509i2.1802
Issue
Vol. 509 No. 2 (2021)
Section
Các bài báo
How to Cite
Công Long, N. ., & Bá Vượng, N. . (2022). RESEARCH ON CHANGES OF AFP, AFP-L3, PIVKA-II BEFORE AND AFTER TREATMENT OF HEPATOCELLULAR CARCINOMA. Vietnam Medical Journal, 509(2). https://doi.org/10.51298/vmj.v509i2.1802

RESEARCH ON CHANGES OF AFP, AFP-L3, PIVKA-II BEFORE AND AFTER TREATMENT OF HEPATOCELLULAR CARCINOMA

Nguyễn Công Long1,, Nguyễn Bá Vượng2
1 Department of Gastroenterology and Hepatology, Bach Mai Hospital
2 Ha Dong General Hospital

Main Article Content

Abstract

Objective: The purpose of this study is to evaluate the role of three markers AFP, AFP-L3, PIVKA-II in evaluating the treatment of patients with hepatocellular carcinoma. Subjects and methods: A total 29 patients with hepatocellular carcinoma participating in the study evaluated the clinical, laboratory and response characteristics of AFP, AFP-L3, PIVKA-II after 1 month of treatment and 3 months. Results: In 29 patients, the mean age of patients was 60.5 ±10.1 years. The risk factors for liver cancer are hepatitis B and C viruses and alcohol. The combination of three markers AFP, AFP-L3 and PIVKA-II increases the sensitivity in the diagnosis of HCC compared with the use of each marker alone. After 1 month and 3 months of treatment with TACE or RFA in HCC patients, mean serum levels of AFP, AFP-L3 and PIVKA-II markers decreased compared with before treatment. Conclusions: The combination of three markers AFP, AFP-L3 and PIVKA-II increases the predictive power of imaging response after treatment of HCC patients compared with the use of each marker alone.

Article Details

Keywords

AFP, AFP-L3, PIVKA-II and Hepatocellular carcinoma

References

1. Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, Negri E: Global trends and predictions in hepatocellular carcinoma mortality. Journal of hepatology 2017, 67(2):302-309.
2. Bosetti C, Turati F, La Vecchia C: Hepatocellular carcinoma epidemiology. Best practice & research Clinical gastroenterology 2014, 28(5):753-770.
3. Park H, Park JY: Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma. BioMed research international 2013, 2013:310427.
4. Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W: Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver cancer 2013, 2(1):31-39.
5. Lim TS, Kim DY, Han KH, Kim HS, Shin SH, Jung KS, Kim BK, Kim SU, Park JY, Ahn SH: Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scandinavian journal of gastroenterology 2016, 51(3):344-353.
6. Bertino G, Ardiri AM, Calvagno GS, Bertino N, Boemi PM: Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer. Drug news & perspectives 2010, 23(8):498-508.
7. Park WH, Shim JH, Han SB, Won HJ, Shin YM, Kim KM, Lim YS, Lee HC: Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Journal of vascular and interventional radiology: JVIR 2012, 23(7):927-936.